Subscribe to Search results

Dr Owen pointed in Parliament to the £500,000 of special financing which was to increase the existing production of Factor 8.

Published on:

Dr Mayne described that haemophilia patients in Northern Ireland who were treated with concentrate received limited quantities of concentrate from Elstree and Oxford.

Published on:

Planning was under way for a new building to constitute BPL at Elstree. A plasma supply target of 435,000 kilograms, including this element for cryoprecipitate production, was broadly maintained with a growing consensus that demand for Factor 8 would increase in the region to around 100 million international units.

Published on:

The UK was self-sufficient in meeting Factor 9 needs, and remained so until products sourced from British donor plasma ceased being used because of the threat of vCJD.

Published on:

Lord Owen described that there was no "reason for anybody who was involved in the Department during that period to hang their head in shame" about steps taken to achieve self-sufficiency.

Published on:

Plasmapheresis first began in the United Kingdom.

Published on:

Professor Dame Marcela Contreras described that the routine recovery of plasma from whole blood donations, especially increased by the separation of red blood cells and the use of SAG-M plasma, were still thought to be the methods of choice, with plasmapheresis making up for the deficit.

Published on:

Dr Biggs maintained that concentrates were the optimum treatment; that commercial product was available but, despite that, UK domestic production should increase; and that home treatment was desirable as a goal.

Published on:

Dr Maycock recognised a need for blood transfusion services to be "self-supporting".

Published on:

The goal of 275,000 donations for Factor 8 production had not been met a year after it had been given.

Published on:

Dr Maycock described that the Department of Health had been advised that the NBTS should reach the position of being able to supply the amount of concentrate from 275,000 donations by 1975, but this was clearly not possible.

Published on:

The DHSS and Dr Maycock understood that it was the supply of plasma for fractionation which needed to increase if the shortfall in meeting anticipated demand was to be met from within the NHS.

Published on:

The SHHD considered that the present dependence on commercial supplies of anti-haemophilic globulin concentrate and PPF posed a threat to the unpaid voluntary donor system.

Published on:

90% of the plasma production for Factor 8 concentrate had already been achieved.

Published on:

It was suggested that plasmapheresis should be practised more widely and rather more intensively than was currently being done.

Published on:

A number of regional transfusion centres had experienced an increase in demand for cryoprecipitate.

Published on:

The unpaid volunteers began donating by plasmapheresis at the North London Blood Transfusion Centre, Edgware.

Published on:

The number of regular attendees at the North London Blood Transfusion Centre, Edgware, exceeded 2,500 and over 80% of the donors attended for donation once a fortnight.

Published on:

It was recommended that SAG-M be introduced as soon as possible, and SAG-M and SAG-S were expected to yield a considerable increase in plasma.

Published on:

Dr Charles Rizza requested the purchase of Immuno Factor 8 concentrates at around £15,000 per year at the Oxford Haemophilia Centre.

Published on: